Management of Metabolic and Alcohol-Related Fatty Liver Disease
Introduction to Fatty Liver Disease Management
- The American Association for the Study of Liver Diseases recommends that adults with metabolic fatty liver disease should restrict all alcohol consumption to reduce liver-related events, as even low alcohol intake doubles the risk of adverse liver outcomes 3
- Heavy alcohol consumption must be discouraged in all patients with alcohol-related liver disease, according to the European Association for the Study of the Liver 2
Lifestyle Interventions
- The American College of Gastroenterology suggests targeting 7-10% body weight reduction through Mediterranean diet and exercise for low-risk patients with metabolic fatty liver disease 1, 5
- Vigorous-intensity exercise (≥6 METs) for at least 150 minutes weekly is recommended, as moderate-intensity exercise does not improve NASH severity or fibrosis, as stated by the American Gastroenterological Association 1
Pharmacologic Treatment
- The American Association for the Study of Liver Diseases recommends considering pioglitazone 30 mg daily in patients with biopsy-confirmed NASH without cirrhosis, and vitamin E 800 IU daily in patients with biopsy-confirmed NASH without diabetes or cirrhosis 1
- GLP-1 receptor agonists (liraglutide, semaglutide) are preferred for patients with type 2 diabetes and NASH/fibrosis, according to the European Association for the Study of Diabetes 5
- Statins are safe and should be used to treat dyslipidemia despite liver disease, as recommended by the American College of Cardiology 1, 5
Management of Alcohol Use Disorder
- The European Association for the Study of the Liver suggests combining counseling with pharmacotherapy: disulfiram, naltrexone, or acamprosate in patients without advanced disease, and using baclofen in patients with advanced alcohol-related liver disease 4
Monitoring and Follow-up
- The American Gastroenterological Association recommends annual follow-up with repeated non-invasive fibrosis assessment for low-risk patients, and follow-up every 6 months with liver function tests and non-invasive fibrosis markers for intermediate/high-risk patients 5, 6
- Cirrhotic patients require hepatocellular carcinoma surveillance every 6 months with ultrasound ± AFP, plus variceal screening, as recommended by the American Association for the Study of Liver Diseases 1, 5